×
About 2,605 results

ALLMedicine™ Apolipoprotein A-I Center

Research & Reviews  1,299 results

Clinical and genetic analysis of KATP variants with heart failure risk in patients with...
https://doi.org/10.1210/clinem/dgab336
The Journal of Clinical Endocrinology and Metabolism; Liu C, Lai Y et. al.

May 13th, 2021 - Lower serum concentration of apolipoprotein A-I (ApoA-I) is causally associated with heart failure (HF) risk. ATP-sensitive potassium channels (KATP), as a gating channel coupling vascular reactivity and metabolism with ischemic protection, become...

Co-administration of CSL112 (apolipoprotein A-I human) with atorvastatin and alirocumab...
https://doi.org/10.1016/j.taap.2021.115557
Toxicology and Applied Pharmacology; Beyerle A, Greene B et. al.

May 1st, 2021 - CSL112 (apolipoprotein A-I, apo AI [human]) is an investigational drug in Phase 3 development for risk reduction of early recurrent cardiovascular events following an acute myocardial infarction (AMI). Although CSL112 is known to be well tolerated...

Baseline cardiometabolic profiles and SARS-CoV-2 infection in the UK Biobank.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8016301
PloS One; Scalsky RJ, Chen YJ et. al.

Apr 1st, 2021 - SARS-CoV-2 is a rapidly spreading coronavirus responsible for the Covid-19 pandemic, which is characterized by severe respiratory infection. Many factors have been identified as risk factors for SARS-CoV-2, with much early attention being paid to ...

Retraction of: Association Between ApoA-I (Apolipoprotein A-I) Immune Complexes and Adv...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8100874
Arteriosclerosis, Thrombosis, and Vascular Biology;

Apr 1st, 2021 - Retraction of: Association Between ApoA-I (Apolipoprotein A-I) Immune Complexes and Adverse Cardiovascular Events.|2021||

Structure dynamics of ApoA-I amyloidogenic variants in small HDL increase their ability...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7890215
Journal of Lipid Research; Nilsson O, Lindvall M et. al.

Jan 7th, 2021 - Apolipoprotein A-I (ApoA-I) of high density lipoproteins (HDLs) is essential for the transportation of cholesterol between peripheral tissues and the liver. However, specific mutations in ApoA-I of HDLs are responsible for a late-onset systemic am...

see more →

Clinicaltrials.gov  1,303 results

Clinical and genetic analysis of KATP variants with heart failure risk in patients with...
https://doi.org/10.1210/clinem/dgab336
The Journal of Clinical Endocrinology and Metabolism; Liu C, Lai Y et. al.

May 13th, 2021 - Lower serum concentration of apolipoprotein A-I (ApoA-I) is causally associated with heart failure (HF) risk. ATP-sensitive potassium channels (KATP), as a gating channel coupling vascular reactivity and metabolism with ischemic protection, become...

Co-administration of CSL112 (apolipoprotein A-I human) with atorvastatin and alirocumab...
https://doi.org/10.1016/j.taap.2021.115557
Toxicology and Applied Pharmacology; Beyerle A, Greene B et. al.

May 1st, 2021 - CSL112 (apolipoprotein A-I, apo AI [human]) is an investigational drug in Phase 3 development for risk reduction of early recurrent cardiovascular events following an acute myocardial infarction (AMI). Although CSL112 is known to be well tolerated...

Baseline cardiometabolic profiles and SARS-CoV-2 infection in the UK Biobank.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8016301
PloS One; Scalsky RJ, Chen YJ et. al.

Apr 1st, 2021 - SARS-CoV-2 is a rapidly spreading coronavirus responsible for the Covid-19 pandemic, which is characterized by severe respiratory infection. Many factors have been identified as risk factors for SARS-CoV-2, with much early attention being paid to ...

Retraction of: Association Between ApoA-I (Apolipoprotein A-I) Immune Complexes and Adv...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8100874
Arteriosclerosis, Thrombosis, and Vascular Biology;

Apr 1st, 2021 - Retraction of: Association Between ApoA-I (Apolipoprotein A-I) Immune Complexes and Adverse Cardiovascular Events.|2021||

Structure dynamics of ApoA-I amyloidogenic variants in small HDL increase their ability...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7890215
Journal of Lipid Research; Nilsson O, Lindvall M et. al.

Jan 7th, 2021 - Apolipoprotein A-I (ApoA-I) of high density lipoproteins (HDLs) is essential for the transportation of cholesterol between peripheral tissues and the liver. However, specific mutations in ApoA-I of HDLs are responsible for a late-onset systemic am...

see more →

News  3 results

ApoA-I Therapies Flop for Plaque Reduction
https://www.medpagetoday.com/cardiology/atherosclerosis/74221

Jul 25th, 2018 - Action Points Two studies of recombinant apolipoprotein A-I (the major HDL apolipoprotein) products failed to show an effect on coronary plaque volume assessed by intravascular ultrasound (IVUS). Note that based on these studies, the development o...

First Oral ApoA-I Booster Shows Mixed Results
https://www.mdedge.com/endocrinology/article/54195/obesity/first-oral-apoa-i-booster-shows-mixed-results
Bruce Jancin

Apr 1st, 2011 - CHICAGO – A novel oral drug designed to increase apolipoprotein A-I synthesis and thereby enhance HDL functionality showed mixed results in its first major clinical trial. The 299-patient, 12-week, randomized, double-blind ApoA-I Synthesis Stimula.

Infusion of Milano Apoprotein Causes Rapid Regression of Atherosclerosis
https://www.medscape.com/viewarticle/463893

Nov 3rd, 2003 - Nov. 4, 2003 — Infusion of the Milano apoprotein A rapidly causes regression of atherosclerosis in patients with acute coronary syndromes (ACS), according to the results of a preliminary randomized trial published in the Nov. 5 issue of The Journa...

see more →